Lins Carvalho, Tatiana; Sanguinett de Almeida, Lilian Maria; Araújo Lorega, Camila Maria; Oliveira Barata, Mirella Francyne; Brito Ferreira, Maria Lúcia; de Brito-Marques, Paulo Roberto; da Cunha Correia, Carolina

Depression and anxiety in individuals with amyotrophic lateral sclerosis: a systematic review


Associação de Psiquiatria do Rio Grande do Sul
Porto Alegre, Brasil

Available in: http://www.redalyc.org/articulo.oa?id=311044979001
Depression and anxiety in individuals with amyotrophic lateral sclerosis: a systematic review

Depressão e ansiedade em pessoas com esclerose lateral amiotrófica: uma revisão sistemática

Tatiana Lins Carvalho,1 Lilian Maria Sanguinett de Almeida,2 Camila Maria Araújo Lorega,2 Mirella Francyne Oliveira Barata,2 Maria Lúcia Brito Ferreira,3 Paulo Roberto de Brito-Marques,4 Carolina da Cunha Correia1

Abstract

Introduction: Studies assessing symptoms of depression and anxiety in individuals with amyotrophic lateral sclerosis (ALS) have reported contradictory results. The objective of this systematic review is to identify the prevalence of these mood disorders in the literature.

Methods: We searched the PubMed, HighWire, MEDLINE, Scielo, LILACS and ScienceDirect databases. Literature was selected for review in two stages, according to eligibility criteria. The first stage involved searching databases and checking titles and abstracts. The second step consisted of reading complete articles and excluding those that did not meet the inclusion criteria. The inclusion criteria were articles written in Portuguese, English or Spanish, published in the last five years and involving people with ALS diagnosed according to the El Escorial criteria.

Results: The database searches returned a total of 1,135 titles and abstracts and then 1,117 of these were excluded. Eighteen articles were selected for review. The 12-item Amyotrophic Lateral Sclerosis Depression Inventory (ADI-12) was the only instrument designed specifically to assess depression in ALS, but it was only used in three studies. No instruments specifically designed for anxiety in ALS were used. A large number of studies found presence and slight increase of anxiety disorders. There was considerable large variation in the results related to depressive disorders, ranging from moderate depression to an absence of symptoms.

Conclusions: Patients with ALS may exhibit symptoms of depression and anxiety at different levels, but there is a need for studies using specific instruments with larger samples in order to ascertain the prevalence of symptoms in ALS and the factors associated with it.

Keywords: Amyotrophic lateral sclerosis, anxiety, depression, incidence, prevalence.

Resumo

Introdução: Estudos avaliando sintomas depressivos e ansiosos em pessoas com esclerose lateral amiotrófica (ELA) têm apresentado resultados contraditórios. Esta revisão sistemática tem por objetivo identificar a prevalência desses transtornos do humor na literatura.

Métodos: A pesquisa foi feita nas bases de dados PubMed, HighWire, MEDLINE, Scielo, LILACS e ScienceDirect. A seleção dos estudos foi realizada em duas etapas de acordo com os critérios de elegibilidade. A primeira etapa envolveu pesquisa nas bases de dados e revisão de títulos e resumos. Na segunda etapa houve leitura dos artigos completos e a exclusão dos que não preen- chiam os critérios de inclusão. Os critérios de inclusão eram: publicação nos idiomas português, inglês ou espanhol, nos últimos 5 anos e envolvendo pessoas com ELA conforme o El Escorial.

Resultados: Um total de 1.135 títulos e resumos foram selecionados, mas 1.117 foram excluídos. Como resultado, 18 artigos foram incluídos na revisão. O Inventário de Depressão da Escle- rose Lateral Amiotrófica com 12 itens (ADI-12) foi o único instrumento específico para avaliação da depressão na ELA utilizado, porém em apenas três estudos. Nenhum instrumento específico para ansiedade na ELA foi utilizado. Boa parte dos estudos apontaram presença e ligeiro aumento das desordens de ansiedade. Já para depressão houve grande diversidade de respostas, variando de depressão moderada à ausência de sintomas.

Conclusões: Pessoas com ELA podem apresentar sintomas depressivos e ansiosos em proporções diferentes, mas há a necessidade de estudos com instrumentos específicos e com amostras mais amplas para que se possa averiguar a prevalência das sintomatologias na ELA e os fatores associados a elas.

Descritores: Esclerose amiotrófica lateral, ansiedade, depressão, incidência, prevalência.
Introduction

It is expected that patients with amyotrophic lateral sclerosis (ALS) will exhibit a high incidence of depression and significant reductions in quality of life. However, studies confirm that there is no direct correlation between progression of the disease and development of depression, anxiety or emotional stress. Perception of physical and functional losses related to the condition has often been shown to cause depressive symptoms during diagnosis, but depression itself has not been clinically proven.¹,²

Studies of the relationship between functional impairment and psychological suffering have reported inconsistent results. While a number of studies have observed positive associations between the seriousness of functional impairment and psychological affliction, others have reported negative correlations between these two variables, finding that people with ALS who were relatively healthy and able to lead normal lives were suffering from deeper depression than those who were physically ill.³

Anguish, fear and concern about the future are often more recurrent in these patients. The way in which patients deal with this condition is related to their social context, in terms of family support and the network of care available to them.¹ This article describes a systematic review carried out to identify whether people with ALS develop symptoms of depression and anxiety when faced with the limiting conditions resulting from the disease.

Methods

Databases, search terms and eligibility criteria

Studies were identified using the PubMed, HighWire, MEDLINE, SciELO, LILACS and ScienceDirect databases during July 2014. The following search terms were used: Amyotrophic Lateral Sclerosis, Depression, Anxiety, Prevalence and Incidence, in different combinations. Inclusion criteria were articles written in Portuguese, English and Spanish, published in the last five years on patients with ALS diagnosed according to the El Escorial criteria. Review or systematic review articles and those involving validation studies or other mood disorders were excluded.

Study selection process

In the first stage of selection three researchers used the search terms to search the databases, assessing titles and abstracts in accordance with eligibility criteria. The abstracts selected then underwent a second stage, in which two other independent researchers reviewed the full texts of articles and by consensus excluded those that did not meet the criteria. Data on sample size and characteristics, time, study type, instruments administered and primary outcomes obtained were extracted from the articles identified as eligible.

Results

The flowchart in Figure 1 illustrates the steps taken to select studies for review. A total of 1,135 titles and abstracts were selected in the first stage and then 1,083 of these were excluded because they did not meet the eligibility criteria or were duplicated. Table 1 lists the combinations of search terms used in the first stage.

After analysis of the full texts of articles (second stage), 34 of the 52 that had initially been selected on the basis of their titles and abstracts were excluded. They were excluded because: the primary topic of the studies considered the presence of depression and anxiety in patients with ALS as secondary; they only studied carers; they were interventions; the studies did not involve humans; or diagnosis of ALS was based on Airlie-House criteria.

Data from the 18 articles included in this systematic review are summarized in Table 2.

A number of limitations were listed by the authors of the studies that met the eligibility criteria. These included the following: small sample size; convenience sample; some patients’ inability to respond to questionnaires, requiring them to be filled out by someone else; absence of a control group; use of antidepressants; nonspecific tests for depression in ALS; patients who attended multidisciplinary clinics were more motivated; sample biased by exclusion of depressed patients; and the possibility that ALS symptoms mask depression symptoms.

Discussion

This systematic review found a predominance of articles assessing depression, with only 7 out of 18 articles investigating anxiety. This may have been a result of the increasing incidence of depressive disorders in the population and because it is considered one of the most debilitating diseases in the world.²⁰

The most widely used tools listed in Table 2 are the Hospital Anxiety and Depression Scale (HADS), Beck’s Depression Inventory (BDI), the Structured Clinical...
Interview for DSM (SCID) and the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV). The 12-item Amyotrophic Lateral Sclerosis Depression Inventory (ADI-12), which is an instrument specifically designed to detect depression symptoms in ALS, was administered in just three studies, leading us to question whether the non-selection of this instrument was because it has not been validated in other countries. It is important to emphasize that using nonspecific instruments may result in inadequate responses, since some studies emphasize the physical symptoms of depression, such as questions involving slowness in performing activities, which are also among the limiting features of ALS progression.

Six of the 18 articles exclusively assessed ALS patients, while the remaining studies made comparisons with control groups. Given the fact that it is considered rare, studies involving this disease generally do not investigate large samples. Eleven of the articles selected had sample sizes of 40 patients with ALS or fewer and their findings may not be representative of the general population.

A significant number of the articles that assessed anxiety disorders reported slight increase in these disorders. In contrast, there was a large variation in the results related to depressive disorders, ranging from moderate depression to an absence of symptoms. Studies suggest that both depression and anxiety should be investigated in patients, since they may exhibit some type of association.\(^\text{4,5,21}\)

---

**Table 1** - Results of the first stage of the systematic review

<table>
<thead>
<tr>
<th>Combination of search terms</th>
<th>Total no. abstracts found</th>
<th>English</th>
<th>Portuguese</th>
<th>Spanish</th>
<th>Total excluded</th>
</tr>
</thead>
<tbody>
<tr>
<td>[Amyotrophic lateral sclerosis and Prevalence and Depression]</td>
<td>41</td>
<td>34</td>
<td>0</td>
<td>59</td>
<td></td>
</tr>
<tr>
<td>[Amyotrophic lateral sclerosis and Prevalence and Anxiety]</td>
<td>44</td>
<td>7</td>
<td>6</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>[Amyotrophic lateral sclerosis and Incidence and Depression]</td>
<td>79</td>
<td>29</td>
<td>30</td>
<td>136</td>
<td></td>
</tr>
<tr>
<td>[Amyotrophic lateral sclerosis and Incidence and Anxiety]</td>
<td>32</td>
<td>5</td>
<td>5</td>
<td>42</td>
<td></td>
</tr>
<tr>
<td>[Amyotrophic lateral sclerosis and Depression]</td>
<td>343</td>
<td>183</td>
<td>120</td>
<td>625</td>
<td></td>
</tr>
<tr>
<td>[Amyotrophic lateral sclerosis and Anxiety]</td>
<td>126</td>
<td>38</td>
<td>13</td>
<td>171</td>
<td></td>
</tr>
</tbody>
</table>
Mood disorders in ALS: a systematic review - Carvalho et al.

<table>
<thead>
<tr>
<th>Identification</th>
<th>Methodology</th>
<th>Main results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atassi et al.¹⁴</td>
<td>Cross-sectional study. 127 people with ALS. ADI-12.</td>
<td>The mean ADI-12 score was 20.3±5.7; 45 (35%) patients had depression and 82 (65%) did not; 29% had mild depression and 6% severe depression; men were more likely to have depression than women (p = 0.01).</td>
</tr>
<tr>
<td>Chen et al.⁵</td>
<td>Cross-sectional study. 93 people with ALS and 93 caregivers. DSM-IV, Hamilton Rating Scale for depression and anxiety.</td>
<td>Fifty-three patients diagnosed with depression (mild = 33; major = 20); 23 caregivers with depression (mild = 18; major = 5). Depression and anxiety in patients and caregivers were closely associated with each other; depression and anxiety disorders are more common in Chinese patients with ALS (57 and 67% respectively) than in their caregivers (24 and 36% respectively).</td>
</tr>
<tr>
<td>Chio et al.⁶</td>
<td>Cross-sectional study. 70 pairs of ALS patients and their caregivers. ZDS.</td>
<td>ZDS = 42.1±9.6; nine (12.9%) patients had mild depression and six (8.6%) had moderate depression; ZDS average = 39.1±7.6; eight (11.4%) caregivers had mild depression.</td>
</tr>
<tr>
<td>Cuddy et al.⁷</td>
<td>Cross-sectional study. 19 patients with ALS and 19 healthy controls. HADSd, ELQ.</td>
<td>There was no significant difference in ELQ scores (z score = -0.5, p = 0.62). People with ALS had higher HADSd scores than controls, but this difference was not significant and mean scores for both groups were in the normal range; there was no association between HADSd scores and emotional processing in either group.</td>
</tr>
<tr>
<td>Ferentinos et al.⁸</td>
<td>Cross-sectional study. 37 patients with ALS. SCID-IV, HADS, ADI-12, CES-D, BDI.</td>
<td>Fourteen (37.8%) patients had major depressive disorder according to the SCID-IV. All four depression severity scores were highly correlated with each other (r &gt; 0.6), except for the ADI-BDI correlation (0.423). Major depressive episodes: eight (21.6%) SCID-IV; six (16.7%) with HADSd ≥ 11.6 (16.2%) with ADI ≥ 29; nine (25%) with CES-D ≥ 24; nine (24.3%) with a BDI-I score ≥ 17.</td>
</tr>
<tr>
<td>Huey et al.³</td>
<td>Cross-sectional study. 13 patients with ALS and 19 with PL. SCID.</td>
<td>Depressive disorders were the most commonly observed psychiatric disorders in ALS; prevalence = 46%.</td>
</tr>
<tr>
<td>Jelsone-Swain et al.¹⁰</td>
<td>Cross-sectional study. 22 patients with ALS and 17 healthy people. GDS, BDI.</td>
<td>Mean GDS scores were higher in patients with ALS 2.32±1.97 than in healthy controls 1.07±1.16, but the scores did not reach the threshold for depression.</td>
</tr>
<tr>
<td>Jakobsson Larsson et al.¹¹</td>
<td>Prospective, longitudinal and descriptive study. 33 patients with ALS. HADS.</td>
<td>Fifteen patients scored 8 or more on HADSa at time point 1 and five at time point 2. Four patients scored 8 or more on HADS at time point 1 and six at time point 2. There were no changes in mean anxiety and depression scores from time point 1 to time point 2.</td>
</tr>
<tr>
<td>Lillo et al.¹²</td>
<td>Cross-sectional study. 92 patients and 81 caregivers. DASS.</td>
<td>More than 70% of the ALS patients did not reach the threshold for depression, but 21% had moderate to severe depression; 18.5% of patients had moderate to severe anxiety.</td>
</tr>
<tr>
<td>Lulé et al.¹³</td>
<td>Cross-sectional study. 30 patients with ALS; 29 people with cancer; 29 healthy controls. BDI.</td>
<td>There was a significant difference between groups for depression: ALS group = 12.90±4.92; cancer patients = 12.10±8.39; controls = 6.24±4.02; F = 10.51, df = 87, p &lt; 0.01. There was also a significant difference between ALS and controls (df = 57, p &lt; 0.01). Both groups of patients had mild to moderate depression.</td>
</tr>
<tr>
<td>Lulé et al.¹⁴</td>
<td>Cross-sectional study. 89 ALS patients, 188 healthy people and 86 primary caregivers. ADI-12.</td>
<td>Mean depression scores were significantly different between groups (ANOVA df = 439, F = 72.71, p &lt; 0.001). Patients’ depression increased slightly with speed of disease progression (Pearson correlation r = 0.26, p = 0.02).</td>
</tr>
<tr>
<td>Marconi et al.¹⁵</td>
<td>Cross-sectional study. 10 ALS patients and 10 caregivers. DSM-IV, SCID II, HADS.</td>
<td>There was a high level of anxiety in patients (11.2±2.1) and caregivers (11.7±2.0). Patients’ scores indicated borderline depression (10.4±2.5) and caregivers’ scores were equivalent to significant depression (11.1±1.5).</td>
</tr>
<tr>
<td>Montel et al.¹⁶</td>
<td>Cohort study. 30 people with ALS. DSM-IV-TR.</td>
<td>Only 27% of the sample suffered from psychological distress at T1; there was no significant correlation between disease severity and psychological suffering.</td>
</tr>
<tr>
<td>Oh et al.³</td>
<td>Cross-sectional study. 62 ALS patients. BDI.</td>
<td>Mean BDI score: 24.5±12.88; 54.8% had depressive symptoms.</td>
</tr>
<tr>
<td>Olsson et al.¹⁷</td>
<td>Cross-sectional study. 35 patients with ALS and 35 relatives. HADS.</td>
<td>There was no change over time in the HADS, but the average anxiety was slightly increased in the first two visits; for depression, the scale was normal for the caregivers who were partners.</td>
</tr>
<tr>
<td>Olsson Ozanne et al.¹⁸</td>
<td>Descriptive study. 35 ALS patients paired with family members. HADS.</td>
<td>There were no differences in HADS scores between patients and their families; patients and relatives had poorer ratings on HADS than the general population.</td>
</tr>
</tbody>
</table>

Note: Table 2 - Data from studies included in the systematic review.

Continued on next page
The studies showed that factors such as age,4,11,18 use of Riluzole,4,19 time from onset of symptoms to diagnosis,4 disease duration4,5,16 and physical disability3,5 were not correlated with depression or anxiety. However, future studies should investigate these mood disorders and the factors that could be involved in this association using larger samples and disease-specific instruments. Limitations of this review were: no articles were identified that administered a specific instrument for anxiety in ALS and few used disease-specific depression instruments; and the reference lists of studies not included were not reviewed.

References


17. Olsson AG, Markhede I, Strang S, Persson LI. Differences in quality of life modalities give rise to needs of individual support in patients with ALS and their next of kin. Palliat Support Care. 2010;8:75-82.


Correspondence:
Tatiana Lins Carvalho
Rua Antônio de Castro, 150/601, Casa Amarela
52070-080 - Recife, PE - Brazil
E-mail: tatiana.lcarvalho@gmail.com